Indeed, modulation of astrocytic reactivity via the JAK2-STAT3 pathway led to reduced amyloid load and improved spatial learning (Ceyzériat et al., 2018), while specific deletion of STAT3 in the APP/PS1 mice model of AD alleviated AD symptoms such as spatial learning and memory impairments, indicating that targeting reactive astrocytes holds therapeutic benefits (Assefa et al., 2018; Reichenbach et al., 2019). The gene discussed is JAK2; the disease is Alzheimer disease.